EZH2 inhibitor proves active in rel/ref NHL

Epizyme plans to report a further update from this trial by the end of this year. The company is now enrolling patients in a phase 2 study of tazemetostat monotherapy in patients with relapsed or refractory NHL, stratified by cell of origin and EZH2 mutation status.

Epizyme is also planning a phase 2 trial of tazemetostat in adults with INI1-deficient solid tumors, a phase 1 study of pediatric patients with INI1-deficient solid tumors, a combination study of tazemetostat with R-CHOP in patients with DLBCL, and a combination study of tazemetostat with a B-cell signaling agent or other emerging targeted therapies for B-cell lymphomas.

*Information in the abstract differs from that presented at the meeting.